Skip to main content
All lobbying filings

W Strategies, LLC

W Strategies, LLC filed a Q3 report for Supernus Pharmaceuticals FKA Sage Therapeutics on October 20, 2025, reporting $50,000 in lobbying income.

Lobbying for Supernus Pharmaceuticals FKA Sage Therapeutics · A clinical-stage biopharmaceutical company.

As filed: W STRATEGIES, LLC for SUPERNUS PHARMACEUTICALS FKA SAGE THERAPEUTICS.

All filings by W Strategies, LLC · Everything Supernus Pharmaceuticals FKA Sage Therapeutics has reported

 Filing · LD-2 quarterly report Q3 report
Reporting period
3rd Quarter 2025
July 1 - Sep 30 · Posted Oct 20, 2025
Income
$50,000
What the client paid this registrant for the period.
Client based in
Massachusetts

Official filing document

 Lobbying activity 1
Health Issues

Education and awareness of mental health issues especially as it relates to access for postpartum depression treatment and major depressive disorder.

 Affiliated organizations 1

Section 6 of the LD-2: organizations that contribute to this lobbying or take an active part in directing it. On a trade association's filing, this is where its backers appear.

  • SUPERNUS PHARMACEUTICALS, INC.
    Rockville, Maryland

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem